In one paragraphArticle in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Ugur OzkerimDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, University of Health Sciences, Istanbul 34865, Turkey.ORCID 0000-0001-8527-1392 Oguzcan KınıkogluDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, University of Health Sciences, Istanbul 34865, Turkey.ORCID 0000-0001-5983-3291 Sila OksuzDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, University of Health Sciences, Istanbul 34865, Turkey.ORCID 0000-0003-4721-0585 Deniz IsikDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, University of Health Sciences, Istanbul 34865, Turkey.ORCID 0000-0003-4398-5148 Yunus Emre AltintasDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, University of Health Sciences, Istanbul 34865, Turkey.ORCID 0000-0002-0634-7350 Sedat YildirimDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, University of Health Sciences, Istanbul 34865, Turkey.ORCID 0000-0002-2423-6902 Goncagul AkdagDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, University of Health Sciences, Istanbul 34865, Turkey.ORCID 0000-0002-6221-0623 Aslı GecgelDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, University of Health Sciences, Istanbul 34865, Turkey.ORCID 0000-0001-6942-9858 Hatice OdabasDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, University of Health Sciences, Istanbul 34865, Turkey.ORCID 0000-0002-5757-4705 Tugba BasogluDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, University of Health Sciences, Istanbul 34865, Turkey.ORCID 0000-0002-2059-5502 Nedim TuranDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, University of Health Sciences, Istanbul 34865, Turkey.ORCID 0000-0002-1140-8779 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
metastatic colorectal canceroxaliplatin-free intervaloxaliplatin rechallengeprogression-free survivalregorafenibthird-line treatment
Identifiers
PMID42794953
PMCPMC13604701
What OpenQuestion holds
Textmetadata
Read underepoch 390